Market Overview

The global anti-venom market was valued at USD 1,240.1 Million in 2024 and is forecasted to reach USD 2,059.7 Million by 2033, growing at a CAGR of 5.8% during 2025-2033. The market is driven by the rising incidence of snakebites and venomous stings, especially in tropical and subtropical regions, supported by government initiatives and advancements in biotechnology. North America currently holds the largest market share of over 37.8% in 2024. For more details, visit the Anti-Venom Market

Study Assumption Years

• Base Year: 2024
• Historical Years: 2019-2024
• Forecast Period: 2025-2033

Anti-Venom Market Key Takeaways

• The global anti-venom market size was USD 1,240.1 Million in 2024.
• The market is expected to grow at a CAGR of 5.8% during the forecast period 2025-2033.
• North America currently dominates the market with over 37.8% share in 2024.
• The incidence of venomous bites such as snakebites and scorpion stings is increasing, driving demand.
• Advances in biotechnology, such as monoclonal antibody-based anti-venoms, are improving treatment efficacy.
• Government initiatives like India's NAP-SE for snakebite prevention contribute to market growth.
• Hospitals remain the primary end users, holding about 62.8% market share due to their critical role in treatment.

Sample Request Link: https://www.imarcgroup.com/anti-venom-market/requestsample

Market Growth Factors

The anti-venom market is primarily driven by the rising incidence of snakebites and venomous insect stings globally, with an estimated 4.5 to 5.4 million snake bites each year, resulting in 81,000 to 138,000 deaths and 1.8 to 2.7 million clinical cases. Factors such as urbanization, deforestation, and climate change have expanded human encounters with venomous species, especially in tropical and subtropical regions, increasing demand for effective treatments.

Advancements in biotechnology have significantly enhanced the development of anti-venoms. The emergence of monoclonal antibody-based anti-venoms offers more effective and targeted therapies with increased safety and faster action. Research in venom immunotherapy and recombinant technology further expands the range of anti-venoms available, lowering production costs and improving treatment accessibility worldwide.

Government and healthcare support play a crucial role in market growth. Many endemic countries allocate funds to procure and distribute anti-venoms, particularly in rural and underserved areas. Programs like India's National Action Plan for Prevention and Control of Snakebite Envenoming (NAP-SE) use a comprehensive "One Health" concept to reduce snakebite deaths by 2030. Partnerships among governments, public health organizations, and NGOs increase awareness and availability, lowering mortality rates and enhancing emergency responses.

Market Segmentation

By Species:

• Snake: Largest segment with approximately 52.3% market share in 2024, driven by the high incidence and severity of snakebites worldwide, especially in tropical and subtropical regions.
• Scorpion
• Spider
• Others

By Anti-Venom Type:

• Polyvalent Anti-venom: Leads with about 66.7% share in 2024 due to its broad-spectrum efficacy against multiple venomous species, making it invaluable in regions with diverse venomous fauna.
• Monovalent Anti-venom

By Mode of Action:

• Neurotoxic: Largest segment at around 32.3% market share in 2024, attributed to the prevalence of neurotoxic envenomation caused by species like cobras and kraits leading to severe clinical outcomes.
• Cytotoxic
• Haemotoxic
• Cardiotoxic
• Myotoxic
• Others

By End User:

• Hospitals: Dominant end user with 62.8% share in 2024 due to equipped facilities, trained personnel, and government programs facilitating timely anti-venom administration.
• Clinics
• Ambulatory Surgical Centers

Regional Insights

North America is the dominant market region in 2024 with a share of over 37.8%. The presence of venomous species such as rattlesnakes, copperheads, and black widow spiders, combined with advanced healthcare infrastructure and government initiatives, drives this demand. The region benefits from technological advances including safer, more effective anti-venoms and extensive research fostering innovations like monoclonal antibody therapies. Public awareness and outdoor activity prevalence further support market expansion.

Recent Developments & News

• August 2024: Three companies, including Echitab Study Limited and Nigeria's Federal Ministry of Health, signed an MoU to locally produce anti-snake venom drugs in Nigeria, aiming to improve affordability and availability.
• August 2024: MicroPharm UK partnered with Nigeria's AMA Medical Manufacturing to establish a facility for affordable anti-venom production, involving a multi-million-dollar investment and technology transfer.
• August 2022: Bharat Serums and Vaccines Ltd. partnered with the Indian Institute of Science (IISc) to develop advanced antivenom therapy to improve treatment outcomes in India.
• March 2022: Ophirex, Inc. received FDA Fast Track designation for varespladib-methyl, an oral broad-spectrum anti-venom, with clinical trials ongoing in the US and India.
• April 2021: Rare Disease Therapeutics, Inc. expanded FDA approval for ANAVIP antivenom to treat all North American Pit Viper envenomation, enhancing treatment availability.

Key Players

• Bharat Serums and Vaccines Limited (BSV)
• Boehringer Ingelheim International GmbH
• Boston Scientific Corporation
• CSL Limited
• Haffkine Bio-Pharmaceutical Corporation Limited
• Incepta Pharmaceuticals Limited
• Merck & Co. Inc.
• Merck KGaA
• MicroPharm Limited
• Pfizer Inc.
• Rare Disease Therapeutics Inc.

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.

Request for customization: https://www.imarcgroup.com/request?type=report&id=5147&flag=E

About Us

IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us

IMARC Group

134 N 4th St. Brooklyn, NY 11249, USA

Email: sales@imarcgroup.com

Tel No: (D) +91 120 433 0800

United States: +1-201971-6302